Ocular Therapeutix
Open
$9.21
Prev. Close
$9.20
High
$9.21
Low
$9.19
Market Snapshot
$1.96B
-7.4
-1.25
$63.72M
325
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
emptyResult
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 325 full-time employees. The company went IPO on 2014-07-25. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Recently from Cashu
Analysts Split on Ocular Therapeutix Pipeline, Regulatory and Commercial Risks
Analysts Split on Ocular Therapeutix's Pipeline Prospects Five independent analyst reports published over the past three months portray a divided view of Ocular Therapeutix, the specialty ophthalmolog…
Divergent Analyst Views Highlight Ocular Therapeutix Clinical and Regulatory Uncertainty
Divergent analyst reports shine a light on clinical and regulatory uncertainty at Ocular Therapeutix Ocular Therapeutix faces a split narrative from sell-side analysts who, over the past three months,…
Analysts Diverge on Ocular Therapeutix Amid Clinical and Regulatory Ambiguity
Analyst divergence highlights clinical and regulatory ambiguity at Ocular Therapeutix Ocular Therapeutix faces a split of opinion among five analysts who publish divergent takes on the company’s near-…
Ocular Therapeutix Expedited NDA Submission for Axpaxli Treatment of Wet AMD
Ocular Therapeutix Accelerates Drug Application for Wet AMD Treatment Ocular Therapeutix Inc. (NASDAQ: OCUL) makes a significant stride in the ophthalmic pharmaceutical sector by announcing the expedi…